Commentary|Articles|June 8, 2026

Hematologists Highlight Top Data From ASCO 2026

Fact checked by: Ashling Wahner , Tracy Ann Politowicz

Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.

Key hematologic oncology data drew attention at the 2026 ASCO Annual Meeting, with key phase 3 trials reading out across the multiple myeloma, diffuse large B-cell lymphoma, and myelofibrosis settings. Here, experts outline some of the top hematology findings shared at the meeting and what these findings may mean for clinical practice.

Related to this article

Image Credit: © LELISAT - stock.adobe.com

September 3rd, 2026

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

September 4th, 2026

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

Lymphoma | Image Credit: © Tongpoon - stock.adobe.com

September 8th, 2026

Real-World Data Highlight Prognostic Value of ctDNA Testing in Lymphomas

Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

September 6th, 2026

Five Under 5: Top Oncology Videos for the Week of 8/31/26

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

September 4th, 2026

OncLive Weekly News Quiz (9/4/2026): Did You Miss Key MPN, Myeloma, and Lung Cancer Updates?

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

September 2nd, 2026

August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

September 11th, 2026

OncLive Weekly News Quiz (9/11/2026): Did You Miss Key Lung Cancer, Myeloma, and Bladder Cancer Updates?

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

September 10th, 2026

ELVN-001 Produces Molecular Responses in Heavily Pretreated CP-CML

The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.